BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
12 August 2024. Related: Antiretrovirals.
Simon Collins, HIV i-Base
In July 2024, Bristol Myers Squibb (BMS) announced plans to discontinue the coformulation of atazanavir/cobicistat (Evotaz) on 30 September 2024.
This is due to declining sales and the availability of newer options for ART.
It is also due to availability of generic versions of each drug.
Doctors are being asked to review anyone currently receiving atazanavir/cobicistat as part of their antiretroviral regimen.
Please contact the BMS Medical Information Department for further information by email or call 0800 731 1736.